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Abstract
Nearly 20% of patients with newly diagnosed osteosarcoma have detectable
metastases at diagnosis; the majority of which occur in the lungs. There are no
established recommendations for the timing and modality of metastasectomy.
Members of the Connective Tissue Oncology Society (CTOS) were emailed an
anonymous 10-min survey assessing their management practices for pulmonary
findings at the time of an osteosarcoma diagnosis. The questionnaire presented
three scenarios and discussed the choice to perform surgery, the timing of
resection, and the choice of surgical procedure. Analyses were stratified by med-
ical profession. One hundred and eighty-three physicians responded to our
questionnaire. Respondents were comprised of orthopedic surgeons (37%),
medical oncologists (31%), pediatric oncologists (22%), and other medical sub-
specialties (10%). There was variability among the respondents in the manage-
ment of the pulmonary nodules. The majority of physicians chose to resect the
pulmonary nodules following neoadjuvant chemotherapy (46–63%). Thoracot-
omy was the preferred technique for surgical resection. When only unilateral
findings were present, the majority of physicians did not explore the contralat-
eral lung. The majority of respondents did not recommend resection if the pul-
monary nodule disappeared following chemotherapy. The survey demonstrated
heterogeneity in the management of pulmonary metastases in osteosarcoma.
Prospective trials need to evaluate whether these differences in management
have implications for outcomes for patients with metastatic osteosarcoma.
Introduction
Osteosarcoma is the most common primary malignant
tumor of bone in children and young adults. At the time
of diagnosis 10–15% of patients have detectable metasta-
ses, of which ~90% occur in the lungs [1, 2]. The pres-
ence of metastatic disease at presentation portends a
worse survival of 30% as compared to greater than 70%
for patients with localized disease [2, 3]. For patients with
localized disease standard treatment involves extirpation
of the primary tumor in conjunction with chemotherapy.
The long-term survival of patients with retained
macroscopic tumor, involving the primary site or metas-
tases, is less than 10% [1].
Aggressive resection of all pulmonary disease has been
shown to prolong survival and be necessary for curative
intent. A retrospective, single-institution review of
patients treated at MD Anderson Cancer Center demon-
strated that patients who underwent resection of pulmo-
nary metastases had a mean survival of 33 months
compared to 10 months for those who did not undergo
resection [4]. However, the major indication for not
undergoing resection was the determination of having un-
resectable disease. The differences in survival may repre-
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sent underlying disparities in the cohorts as those that
did not undergo resection may have had more advanced
disease or more aggressive biology.
Another confounding variable is the lack of clarity of
what represents metastatic disease. In the MD Anderson
review greater than 5% of the patients who underwent
resection were found not to have osteosarcoma metastases
[4]. The most frequently used modality for defining meta-
static disease is the visualization of nodules on computed
tomography (CT) of the chest. Due to the limits of radio-
graphic imaging, some osteosarcoma lesions are palpable
even though they have not been previously visualized.
Kayton, et al. found in a retrospective comparison
between CT imaging and pathologic review that CT
underestimated the number of metastases in 35%, overes-
timated in 37%, and demonstrated concordance in 28%
of the cases. Of the 329 lung nodules resected in 54 tho-
racotomies only 63.5% were pathologically confirmed to
be osteosarcoma metastases. Fifteen percent of the thora-
cotomies did not demonstrate any pathologically con-
firmed osteosarcoma despite the imaging findings [5]. In
contrast, patients who present with unilateral metastases
on CT imaging frequently have palpable disease on explo-
ration of the contralateral lung [6].
It is important to note, however, that imaging technol-
ogy has considerably improved in the time period follow-
ing the publication of these studies, and radiologists are
now better equipped to identify pulmonary metastases in
osteosarcoma. More recently, a review by Brader, et al. of
117 nodules demonstrated greater than 93% accuracy in
identification of malignant nodules using independent
predictors of malignant risk including calcifications and
size greater than 5 mm [7]. However, radiologists from
the study were unable to accurately identify benign
nodules and mislabeled over 70% of benign nodules as
malignant suggesting that a large portion of patients may
continue to be at risk of morbidity from unnecessary
thoracic procedures.
There is also a lack of consensus regarding the clinical
relevance of palpable osteosarcoma metastases that are
not detectable on CT imaging. Karplus, et al., in a retro-
spective review of patients at St. Jude who underwent
unilateral thoracotomy for unilateral disease, found that
early relapses, occurring within 6 months, recurred with
equal likelihood in the ipsilateral (11%) versus the con-
tralateral (12%) lung. Overall, following unilateral resec-
tion, 17% of patients recurred on the ipsilateral versus
27% on the contralateral side, and 3% developed bilateral
metastases [8]. There was no statistical difference in these
groups, leading the authors to conclude that occult
metastases may have uncertain clinical significance.
Given the lack of definitive evidence to define practice
patterns for patients with metastatic disease the
recommendation from the National Comprehensive
Cancer Network (NCCN) guidelines, clinical trials, and
expert opinion is, when feasible, to completely resect all
metastatic disease. There are no consensus recommenda-
tions for what defines metastatic disease in osteosarcoma,
the timing of resection, or the surgical approach. To
define normative practice patterns, the authors report the
results of an online questionnaire addressed to members
of the Connective Tissue Oncology Society (CTOS)
regarding their views on the surgical management of
pulmonary metastases in osteosarcoma.
Materials and Methods
Study population
The Connective Tissue Oncology Society (CTOS) is an
organization dedicated to improving outcomes for
patients with tumors of the connective tissue. The society
consists of pediatric oncologists, medical oncologists, sur-
gical oncologists, radiation oncologists, orthopedic sur-
geons, cardiothoracic surgeons, pathologists, radiologists,
and scientists and has over 400 members. Members of
CTOS were emailed a link to an anonymous survey
regarding their views on the surgical management of pul-
monary metastases in osteosarcoma. Only one response
could be submitted from a given IP address. This study
was approved by the Institutional Review Board of the
Montefiore Medical Center and the Albert Einstein Col-
lege of Medicine.
Questionnaire
Participants were asked questions regarding their
management decisions for pulmonary metastases in osteo-
sarcoma. The questionnaire used a “choose your own
adventure” format with follow-up questions varying based
on the responses to prior questions. The questionnaire
focused on three scenarios in which an 18-year-old boy
presents with a new diagnosis of osteosarcoma of the left
distal femur and pulmonary nodules on imaging: a single
unilateral 2 cm nodule, a single unilateral 0.5 cm nodule,
and multiple bilateral nodules.
The primary outcome was the decisions related to the
management of the pulmonary nodules in each scenario.
Respondents were interrogated regarding their views in
each scenario for the need for resection, whether response
to chemotherapy influenced their views, the timing of
resection, surgical approach including thoracoscopy, tho-
racotomy, sternotomy, and the need for exploration of
the contralateral lung. Secondary outcomes included vari-
ability in management as they pertained to demographic
characteristics.
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Statistical methods
Descriptive statistics were computed for participant
demographic characteristics. Bivariate analyses involving
management decisions and physician characteristics were
evaluated by t-test for continuous variables and chi-
squared test for categorical variables.
Results
Demographic data
One hundred and eighty-three participants completed the
questionnaire. Respondents included orthopedic surgeons
(37%), medical oncologists (31%), pediatric oncologists
(22%), radiation oncologists (5%), pathologists (2%), and
pediatric surgeons, surgical oncologists, and “other” (each
totaling 1%). Fifty-four percent of physicians reported
completion of medical training in the United States, and
40% completed training outside of the United States. The
majority of respondents practiced in an academic medical
center (60%) or a cancer center (26%). Physicians were
practicing for a median of 10–20 years and saw a median
of 8–10 osteosarcoma patients a year with wide distribu-
tion in both categories. Most commonly the respondents
(43%) reported that national guidelines were the predom-
inant factors guiding their clinical management decisions
(Table 1).
Timing of resection
The majority of physicians (63%) chose to manage a
unilateral 2 cm nodule after neoadjuvant chemotherapy
was completed, whereas 10% chose to manage the
nodule prior to initiation of treatment and 27% deferred
management until completion of all planned chemother-
apy. The percentage of respondents addressing the
nodule at the time of completion of neoadjuvant chemo-
therapy decreased significantly when presented with the
scenarios of 0.5 cm nodule and multiple bilateral nodules
(51%, P = 0.03, and 46%, P = 0.002, respectively)
(Fig. 1).
If the survey participants chose to defer management
of the nodules until after neoadjuvant chemotherapy or
after completion of all planned chemotherapy, they were
told that the primary tumor had >90% necrosis and pre-
sented with additional scenarios of the nodule remaining
unchanged, decreased in size, or disappeared altogether.
Of the 166 respondents who chose to defer management
of a solitary 2 cm nodule, 78% believed management
was complete when the nodule disappeared on repeat
imaging. This practice was not statistically significantly
different in the subcentimeter or multiple bilateral
nodules scenarios (80% and 72%, respectively) (Figs. 1
and 2).
The respondents who chose to forego exploration of
the lung with the disappeared nodule were then asked
their perception of nodule. The majority believed that the
disappeared nodule represented chemoresponsive disease
(66%, 55%, and 60%, in the 2 cm, 0.5 cm, and multiple
bilateral nodules, respectively). In the 0.5 cm nodule sce-
nario, there was a statistically significant increase in the
percentage of respondents who believed that the disap-
peared nodule represented an incidental finding (16%,
P = 0.015 and P = 0.002 when compared with the 2 cm
(7%) and multiple bilateral nodules (5%) scenarios)
(Fig. 2).
Table 1. Demographics.
Medical discipline
Pediatric oncologist 41 22%
Medical oncologist 57 31%
Orthopedic surgeon 68 37%
Pediatric surgeon 1 1%
Radiation oncologist 9 5%
Surgical oncologist 2 1%
Pathologist 3 2%
Other/skipped 2 1%
Years from training
0–5 28 15%
5–10 42 23%
10–20 51 28%
20+ 51 28%
Skipped 8 4%
Medical education
United States 98 54%
Outside US 74 40%
Skipped 11 6%
Location of current practice
Cancer Center 48 26%
Academic medical center 110 60%
Private practice affiliated with
academic medical center
2 1%
Private practice unaffiliated with
academic medical center
8 4%
Other 1 1%
Skipped 14 8%
Number of osteosarcoma pts seen per year
0–3 20 11%
4–7 67 37%
8–10 29 16%
10+ 55 31%
Skipped 12 7%
Factor that Predominantly Guides
Clinical Management Decision
National Guidelines (e.g., NCCN) 78 43%
Institutional policies/standards 42 23%
Personal clinical practice and experience 51 28%
Skipped 12 7%
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Surgical technique
Thoracotomy was the most preferred technique for resec-
tion across all scenarios. Thoracoscopy was the preferred
modality (58%) only for the few respondents who chose
to address the 2 cm and the 0.5 cm nodules in the
pretreatment period. In the scenario of multiple bilateral
nodules, most respondents, regardless of the scenario
faced, expressed their preference for performing a
thoracotomy. Thoracoscopy was never suggested when
the nodules had completely disappeared (Table 2).
In every scenario in which the respondents resected the
nodule, they were informed that the pathology was con-
sistent with metastatic osteosarcoma. The participants
were then questioned if they would consider surgery on
the contralateral lung. Only in the scenario of multiple
bilateral nodules did the majority of the respondents sug-
gest performing exploration of the contralateral lung. This
10%
60% 55%
11%
26% 24%
3%
2% 5%
48% 1%
3% 23%
1% 3% 4%
1% 1%
0%
20%
40%
60%
80%
100%
. Unchanged Decreased Disappeared Unchanged Decreased Disappeared
Pre-treatment After neoadjuvant Post-treatment
2.0 cm nodulea
Skipped
No resection
Resection 
7% 37%
10% 22% 3%
11%
38% 14% 33%
1% 4%
0%
20%
40%
60%
80%
100%
. Unchanged Decreased Disappeared Unchanged Decreased Disappeared
Pre-treatment After neoadjuvant Post-treatment
0.5 cm noduleb
4%
37%
11%
33%
8%
5%
31%
10%
36%
7%
0%
20%
40%
60%
80%
100%
. Unchanged Decreased Disappeared Unchanged Decreased Disappeared
Pre-treatment After neoadjuvant Post-treatment
Multiple bilateral nodulesc
[27%]
[36%]
[51%]
[43%]
[63%]
[46%]
Figure 1. Timing of initiation of management and resection for 2.0 cma, 0.5 cmb, and multiple bilateralc nodules. an = 183 survey responders.
Significantly more 2.0 cm are managed at pretreatment than multiple bilateral (P = 0.0235). bn = 183 survey responders. Significantly less 0.5 cm
are managed after neoadjuvant therapy than 2.0 cm (P = 0.03). cn = 183 survey responders. Significantly less multiple bilateral nodules are
managed after neoadjuvant therapy than 2.0 cm (P = 0.002). Decreased not option for the respondents in the case of 0.5 cm nodule or multiple
bilateral nodules.
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was a statistically significant difference when compared
with both the 2 and 0.5 cm nodule scenarios regardless of
the timing of the resection or the response to chemother-
apy (Fig. 3).
Variation in management by specialty
When the management decisions were further analyzed by
demographic data, clear differences were noted between
medical and pediatric oncologists. Medical oncologists in
every scenario were more likely to delay the timing of
surgical resection until completion of all planned chemo-
therapy (38–53%) versus (10–23%) (Table 3). Pediatric
oncologists were significantly more likely than medical
oncologists to explore the contralateral lung in both the
2 cm and the 0.5 cm scenarios, although a minority of
respondents made that recommendation in these scenar-
ios. Orthopedic surgeons did not significantly deviate in
their management from pediatric or medical oncologists
(data not shown). As noted before, the majority of respon-
dents regardless of their specialty recommended contralat-
eral lung resection in the scenario with multiple bilateral
lung nodules (Table 4).
The number of years since completion of training
revealed differences in the management of small nodules.
Physicians who were practicing for more than 5 years
versus physicians with less than 5 years experience were
significantly more likely to recommend thoracotomy for
the 2 cm nodules that had decreased in size after chemo-
therapy (77% vs. 48%, P = 0.0085) and for the 0.5 cm
nodules (76% vs. 38%, P = 0.0057). There were no differ-
ences between these groups in the management of the
2 cm unchanged nodule and multiple bilateral nodules,
with the majority of respondents preferring thoracotomy
(Table 5).
All the other demographic data were examined, and no
statistical significant differences were observed in the
management of the scenarios presented (data not shown).
66%
55% 60%
7%
16% 5%
5% 9%
7%
16% 14%
21%
5% 4% 7%
0%
20%
40%
60%
80%
100%
2.0 cm, n = 166 0.5 cm, n = 159 Multiple bilateral, n = 168
Skipped Resection Management 
complete, other
Management 
complete, assume 
incidental
Management 
complete, assume 
chemoresponsive
Figure 2. Reasons for not resecting after nodules disappeared after neoadjuvant therapy or posttreatmenta.
Table 2. Surgical technique of resections performed; unchanged,
decreased, and disappeared include responses from both after neoad-
juvant and posttreatment.
Thoracoscopy Thoracotomy Sternotomy
2.0 cm
Pretreatment, n = 19 58% 42% 0%
Unchanged, n = 120 21% 69% 10%
Decreased, n = 144 21% 73% 6%
Disappeared, n = 27 0% 78% 22%
0.5 cm
Pretreatment, n = 12 58% 42% 0%
Unchanged, n = 107 25%1 69% 6%
Disappeared, n = 23 0% 78% 22%
Multiple bilateral
Pretreatment, n = 7 29% 71% 0%
Unchanged, n = 129 12%1 77% 12%
Disappeared, n = 35 0% 80% 20%
1Significantly more thoracoscopies performed in 0.5 cm nodules than
multiple bilateral nodules (P < 0.01).
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Discussion
This survey presented three clinical scenarios to treating
physicians with interest in malignancies of bone and dem-
onstrated variability in the practice patterns in the man-
agement of pulmonary metastases in osteosarcoma. In all
three scenarios, most respondents elected to manage the
pulmonary nodules following neoadjuvant chemotherapy.
A small minority of the respondents opted to resect the
nodules prior to initiating neoadjuvant chemotherapy,
and the remainder chose to resect at the end of planned
chemotherapy.
10%
49% 45%
4% 6%
23% 3%
11% 10%
8%
1%
2%
9%
52%
21%
3%
24%
0%
20%
40%
60%
80%
100%
Unchanged Unchanged Decreased Disappeared Unchanged Decreased Disappeared
Pre-treatment After neoadjuvant Post-treatment
2.0 cm nodulea No resection/skipped
Bilateral
Ipsilateral
7%
29%
3% 20% 2%
8%
7%
2%
1%
12%
42%
14%
33%
0%
20%
40%
60%
80%
100%
Unchanged Unchanged Decreased Disappeared Unchanged Decreased Disappeared
Pre-treatment After neoadjuvant Post-treatment
0.5 cm noduleb,c
1% 1% 1% 2% 1%
3% 36% 11% 31%
7%
5%
37%
10%
36%
0%
20%
40%
60%
80%
100%
Unchanged Unchanged Decreased Disappeared Unchanged Decreased Disappeared
Pre-treatment After neoadjuvant Post-treatment
Multiple bilateral nodulesc
Figure 3. Contralateral lung exploration of total responders for 2.0 cma, 0.5 cmb, and multiple bilateralc nodules*. an = 183 survey responders.
Significantly less 2.0 cm had contralateral exploration than multiple bilateral in after neoadjuvant unchanged (P < 0.0001), After neoadjuvant
disappeared (P < 0.0001), posttreatment unchanged (P < 0.0001), and posttreatment disappeared (P = 0.0004). bn = 183 survey responders.
Significantly less 0.5 cm had contralateral exploration than multiple bilateral in after neoadjuvant unchanged (P < 0.0001), After neoadjuvant
disappeared (P < 0.0001), posttreatment unchanged (P < 0.0001), and posttreatment disappeared (P = 0.0029). cn = 183 survey responders.
Decreased not option for the respondents in the case of 0.5 cm nodule or multiple bilateral nodules.
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Variability was demonstrated not only in the timing of
resection, but also differences in the percentages were
noted depending on the clinical scenario. This suggests
that variability exists not only between the respondents,
but also within the practice pattern of individual
clinicians depending on the patient’s presentation. Like-
wise, while thoracotomy was the preferred surgical
modality for resection of the pulmonary nodules, the use
of thoracoscopy varied based on the clinical scenario and
the number of years in practice. Most respondents chose
not to explore the contralateral lung unless radiographic
evidence of bilateral disease was presented in the scenario
with multiple bilateral nodules. In this practice there were
differences between pediatric and medical oncologists,
with a higher percentage of pediatric oncologists electing
to explore the contralateral lung in the scenarios with the
single lung nodule. In the situation that the nodule disap-
peared, most respondents elected to forgo exploration of
the ipsilateral lung, attributing the change to chemore-
sponsive disease.
The data on the treatment of pulmonary metastases in
osteosarcoma are limited to a few case series from which
no definitive conclusions can be made. The most inclusive
review of lung metastasectomy was presented by the
International Registry of Lung Metastasis. This database
included 5206 cases of varying histologies (42% sarcomas)
collected from major centers of thoracic surgery and
found that primary tumor type, disease-free interval
(DFI), and the number of metastases are the most signifi-
cant prognostic factors. Based on these variables, they
developed prognostic grouping demonstrating that
patients with resectable disease with a DFI greater than
36 months and a single metastasis had the best outcomes
with those with unresectable disease having the worst [9].
While this information establishes a baseline for risk-ben-
efit assessment, it still contains the underlying limitations
of a case series, further confounded by the difference in
outcomes noted for the different histologies included. As
this study did not randomize patients, it does not estab-
lish a survival advantage of surgery. The registry demon-
strated variability in the accuracy of the preoperative
imaging as well as in the surgical modalities utilized.
Given the multiple variables, the authors could not make
conclusions about the superiority of any surgical tech-
nique.
Without clear evidence to define management, practice
patterns are based on national guidelines and expert
opinion. The NCCN guidelines for metastatic osteosar-
coma recommend surgery for all resectable disease. Like-
wise, the Children’s Oncology Group protocols for
patients with metastatic osteosarcoma recommend resec-
tion of all disease when deemed feasible. This survey is
the first to assess practice patterns of treating physicians
Table 3. Initiation of management in posttreatment period between
pediatric and medical oncologists.
Pediatric
oncologist
Medical
oncologist
Significance,
P-value
2.0 cm1 10% 38% 0.004
0.5 cm2 23% 53% 0.005
Multiple Bilateral3 21% 45% 0.04
1n = 39 pediatric oncologists and 56 medical oncologists.
2n = 39 pediatric oncologists and 53 medical oncologists.
3n = 38 pediatric oncologists and 53 medical oncologists.
Table 4. Contralateral exploration of unchanged nodules between
pediatric and medical oncologists; includes nodules managed both
after neoadjuvant therapy and posttreatment; includes nodules man-
aged both after neoadjuvant therapy and posttreatment.
Pediatric oncologist Medical oncologist P-value
2.0 cm1 19% 2% 0.01
0.5 cm2 28% 6% 0.04
Multiple bilateral3 100% 80% 0.12
1n = 32 pediatric oncologists and 51 medical oncologists who
reported resections.
2n = 29 pediatric oncologists and 33 medical oncologists who
reported resections.
3n = 32 Pediatric Oncologists and 40 medical oncologists who
reported resections.
Table 5. Surgical technique of unchanged and decreased nodules
between responders who completed training 0–5 years ago and
5+ years ago; includes nodules managed in both after neoadjuvant
therapy and posttreatment.
0–5 years 5 years P-value
2.0 cm
Unchanged1
Thoracoscopy 29% 22% 0.5743
Thoracotomy 67% 70% 0.8001
Decreased2
Thoracoscopy 48% 17% 0.003
Thoracotomy 48% 77% 0.0085
0.5 cm
Unchanged3
Thoracoscopy 56% 19% 0.0032
Multiple bilateral
Unchanged4
Thoracotomy 38% 76% 0.0057
Thoracoscopy 18% 10% 0.398
Thoracotomy 76% 77% 1.000
1n = 100 (0–5 years) and 80 (5+ years).
2n = 21 (0–5 years) and 121 (5+ years).
3n = 16 (0–5 years) and 90 (5+ years).
4n = 17 (0–5 years) and 111 (5+ years).
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in the management of osteosarcoma lung metastases. In
accordance with these guidelines, most of the clinicians
surveyed advocated for resection of disease when it was
still radiographically detectable. However, given the pau-
city of guidance, there was limited conformity in the
practice patterns between the physicians and between the
different clinical scenarios.
Similar variability in management of pulmonary metas-
tasectomy was demonstrated by Internullo, et al. in a sur-
vey of members of the European Society of Thoracic
Surgeons. The survey included metastasectomy of multi-
ple tumor types, and found that the major areas of con-
cern and contraindication for surgery were unresectable
primary or unresectable metastatic disease. Consistent
with the results from this survey, the majority of thoracic
surgeons considered palpation mandatory, but had a
more extensive list and increased variability of approaches
utilized. The thoracic surgeons, like the respondents in
this survey, demonstrated heterogeneity in their approach
based on patient-specific variables, tailoring care based on
presentation [10]. The survey by Internullo et al. had a
difference in scope and so did not inquire about timing
of resection nor about differences in management based
on the changes of the metastatic lesions during treatment.
Internullo et al. also discuss that although a majority of
the thoracic surgeons who responded recommended
palpation, very few advocated for a bilateral approach.
Other factors not included in this survey may further
increase the variability in the timing and method of resec-
tion of pulmonary metastases. The location of the pri-
mary tumor in this survey was uniform to minimize the
effects of the definitive surgery as a confounding variable.
However, a proximal humerus lesion may require further
delay in metastasectomy to promote healing, whereas a
chest wall primary, given the opportunity, may warrant
metastasectomy at the time of definitive surgery, poten-
tially leading to further variability in the management of
the pulmonary nodules. One demographic factor that was
not considered in this study was the geographic region of
practice of the survey participants within the United
States. Several regions within the country are associated
with endemic fungal infections, and the prevalence of
these pathogens may influence the incidence of pulmo-
nary findings within the regional population. It would be
of note if the geographic region of practice influenced
management preferences of indeterminate lung nodules.
The major limitation of this study is the limitation of
the instrument used. The respondents were presented
with three contrived scenarios and limited choices to
which to define their management preferences. Likewise,
this survey relies on self-report, and as such may not
accurately recapitulate real-world practice patterns. Many
of the respondents provided very thoughtful comments
reflecting the art of medicine beyond the scope of this
questionnaire. They noted that the appearance, not just
the size, of the nodules on the radiographic imaging may
be more informative and affect their management choices.
Many respondents commented that when the nodules dis-
appeared on repeat imaging, they remained concerned
and would recommend close surveillance with serial
imaging. Lastly, the management of metastatic osteosar-
coma requires a multidisciplinary effort, and the thoracic
surgeons, who are a key component of that team, as well
as the collaborative effort involved in the decision-making
process were underrepresented in this survey.
In conclusion, this study found that there is variability
in the reported management of pulmonary nodules in
patients with osteosarcoma. Future studies need to address
the uncertainty in the management of pulmonary metasta-
ses and prospectively collect data and evaluate if differ-
ences in timing, surgical technique, and exploration of the
contralateral lung have implications for the outcomes of
patients with osteosarcoma and pulmonary metastases.
Acknowledgments
The authors thank the members of CTOS and the admin-
istrative staff for volunteering their time and effort for
the conduct of this survey. We also thank the Board of
CTOS for granting permission to distribute this survey
through their membership.
Conflict of Interest
None declared.
References
1. Bielack, S. S., B. Kempf-Bielack, G. Delling, G. U. Exner, S.
Flege, K. Helmke, et al. 2002. Prognostic factors in high-
grade osteosarcoma of the extremities or trunk: an analysis
of 1702 patients treated on neoadjuvant cooperative
osteosarcoma study group protocols. J. Clin. Oncol.
20:776–790.
2. Chou, A. J., E. S. Kleinerman, M. D. Krailo, Z. Chen, D. L.
Bletcher, J. H. Healey, et al. 2009. Addition of muramyl
tripeptide to chemotherapy for patients with newly
diagnosed metastatic osteosarcoma: a report from the
Children’s Oncology Group. Cancer 115:5339–5348.
3. Meyers, P. A., C. L. Schwartz, J. H. Healey, M. L.
Bernstein, D. Betcher, W. S. Ferguson, et al. 2008.
Osteosarcoma: the addition of muramyl tripeptide to
chemotherapy improves overall survival—a report from
the Children’s Oncology Group. J. Clin. Oncol.
26:633–638.
4. Harting, M. T., M. L. Blakely, N. Jaffe, C. S. Cox Jr., A.
Hayes-Jordan, R. S. Benjamin, et al. 2006. Long-term
530 ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Variability in Management of Metastases O. Bhattasali et al.
survival after aggressive resection of pulmonary metastases
among children and adolescents with osteosarcoma. J.
Pediatr. Surg. 41:194–199.
5. Kayton, M. L., A. G. Huvos, J. Casher, S. J. Abramson, N.
S. Rosen, L. H. Wexler, et al. 2006. Computed
tomographic scan of the chest underestimates the number
of metastatic lesions in osteosarcoma.
J. Pediatr. Surg.. 41:200–206; discussion 200–206.
6. Su, W. T., J. Chewning, S. Abramson, N. Rosen, M.
Gholizadeh, J. Healey, et al. 2004. Surgical management
and outcome of osteosarcoma patients with unilateral
pulmonary metastases. J. Pediatr. Surg..
39:418–423; discussion 418–423.
7. Brader, P., S. J. Abramson, A. P. Price, N. M. Ishill, E. C.
Zabor, C. S. Moskowitz, et al. 2011. Do characteristics of
pulmonary nodules on computed tomography in children
with known osteosarcoma helped distinguish whether the
nodules are malignant or benign? J. Pediatr. Surg. 46:729–
735.
8. Karplus, G., M. B. McCarville, M. P. Smeltzer, G. Spyridis,
B. N. Rao, A. Davidoff, et al. 2009. Should contralateral
exploratory thoracotomy be advocated for children with
osteosarcoma and early unilateral pulmonary metastases? J.
Pediatr. Surg. 44:665–671.
9. Pastorino, U., M. Buyse, G. Friedel, R. J. Ginsberg, P.
Girard, P. Goldstraw, et al. 1997. Long-term results of lung
metastasectomy: prognostic analyses based on 5206 cases.
The International Registry of Lung Metastases. J. Thorac.
Cardiovasc. Surg.. 113:37–49.
10. Internullo, E., S. D. Cassivi, D. Van Raemdonck, G.
Friedel, and T. Treasure, Group EPMW. 2008. Pulmonary
metastasectomy: a survey of current practice amongst
members of the European Society of Thoracic Surgeons.
J. Thorac. Oncol.. 3:1257–1266.
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 531
O. Bhattasali et al. Variability in Management of Metastases
